Billiontoone (NASDAQ:BLLN) Reaches New 52-Week Low – Here’s Why

Billiontoone, Inc. (NASDAQ:BLLN)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $78.28 and last traded at $78.28, with a volume of 89205 shares changing hands. The stock had previously closed at $85.42.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BLLN. Stifel Nicolaus started coverage on shares of Billiontoone in a research report on Monday, December 1st. They set a “buy” rating and a $145.00 target price on the stock. Wall Street Zen raised Billiontoone to a “hold” rating in a report on Saturday, November 15th. BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Billiontoone in a research note on Wednesday, December 10th. Wells Fargo & Company started coverage on shares of Billiontoone in a research report on Monday, December 1st. They set an “equal weight” rating and a $110.00 target price for the company. Finally, Guggenheim assumed coverage on Billiontoone in a research note on Tuesday, January 6th. They issued a “buy” rating and a $120.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $135.29.

Billiontoone Trading Down 15.6%

The firm’s 50 day moving average price is $89.07. The firm has a market capitalization of $3.30 billion and a P/E ratio of 721.00.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.06). The company had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.

Hedge Funds Weigh In On Billiontoone

Hedge funds have recently added to or reduced their stakes in the stock. Adams Street Partners LLC bought a new position in Billiontoone during the fourth quarter worth about $140,063,000. Baillie Gifford & Co. bought a new position in Billiontoone during the 4th quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the 4th quarter worth approximately $39,717,000. JPMorgan Chase & Co. acquired a new position in Billiontoone during the fourth quarter valued at approximately $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Billiontoone in the fourth quarter valued at approximately $18,631,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.